Effects of Lianhua Qingwen Granules Plus Arbidol on Treatment of Mild Corona Virus Disease-19
- VernacularTitle: 连花清瘟颗粒联合阿比多尔治疗轻度新型冠状病毒肺炎的疗效观察
- Author:
Ping YU
1
Author Information
- Publication Type:Journal Article
- Keywords: Arbidol; Clinical effect; Corona virus disease-19; Lianhua Qingwen granules
- From: Chinese Pharmaceutical Journal 2020;55(12):1042-1045
- CountryChina
- Language:Chinese
- Abstract: OBJECTIVE: To discuss the effects of Lianhua Qingwen granules plus arbidol on treatment of mild corona virus disease-19 (COVID-19). METHODS: A total of 295 COVID-19 patients (2020.2.17-2020.3.6) in Wuhan Third Hospital were chosen and randomly assigned to control group (n=148) and observation group (n=147). The control group orally took arbidol and the observation group took Lianhua Qingwen granules and arbidol. TCM symptom scores, white blood count (WBC), lymphocyte count (LYM), C-reactive protein (CRP), procalcitonin (PCT) and chest CT review conditions were compared. RESULTS: Total effective rate in the observation group was significantly higher than control group ((80.95% vs. 64.86%); severe transfer rate in the observation group was lower than control group (14.29% vs. 23.65%) (P0.05); after 7 d of treatment, TCM syndromes like fever, weakness, cough, throat dryness and sore and chest discomfort, CRP and PCT levels in the observation group were significantly lower than control group (P0.05); WBC and LYM levels in the observation group were significantly higher than control group (P0.05); based on CT review, effective cure rate in the observation group (69.39%) and control group (62.84%) was not significantly different (P0.05). Both of groups had no serious adverse reactions. CONCLUSION: Lianhua Qingwen granules combined with arbidol can relieve the clinical symptoms, adjust the inflammatory factors, increase the curative effects and reduce the severe transfer rate.
